Asciminib: first FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia
Crossref DOI link: https://doi.org/10.1007/s00044-022-03011-9
Published Online: 2023-02-02
Published Print: 2023-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
De, Surya K. http://orcid.org/0000-0001-5014-0798
Text and Data Mining valid from 2023-02-02
Version of Record valid from 2023-02-02
Article History
Received: 8 November 2022
Accepted: 19 December 2022
First Online: 2 February 2023
Compliance with ethical standards
:
: The authors declare no competing interests.